Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383 and Sui, Jessica 2016. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs? Thrombosis Research 140 (S1) , S154-S159. 10.1016/S0049-3848(16)30115-3 |
Abstract
Whilst the term cancer associated thrombosis (CAT) offers an overarching term for all thrombotic events encountered during the cancer journey, the reality is that this is a far too simplistic reflection of a complex multifactorial process occurring within a heterogeneous population. The management of CAT needs to consider factors beyond the thrombus itself: patients must be treated as individuals within the context of their own cancer journey and their preferences for different treatment options. The breath of pathological, pharmacological and psychosocial variants means it is highly unlikely that one treatment regime will be appropriate for all patients. It is inevitable that regimes may need to be modified and anticoagulant agents changed according to clinical and patient preference needs. There is strong evidence supporting the use of low molecular weight heparin first line in the treatment of acute CAT. The evidence for warfarin and the direct acting oral anticoagulants is not as strong but, as oral agents, may be preferred by some patients. This paper shall identify the various treatment options available, factors which will influence the decision making process and when it is justifiable to treat patients differently to the established protocol.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Uncontrolled Keywords: | Cancer associated thrombosis, Individual care, LMWH, DOACs, Patient preference |
Publisher: | Elsevier |
ISSN: | 0049-3848 |
Last Modified: | 22 Oct 2022 13:32 |
URI: | https://orca.cardiff.ac.uk/id/eprint/103980 |
Citation Data
Cited 15 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |